Selpercatinib: First approved selective RET inhibitor.
Cell
; 186(8): 1517, 2023 04 13.
Article
em En
| MEDLINE
| ID: mdl-37059058
ABSTRACT
Selpercatinib is a small molecule that binds at the RET kinase active site. It inhibits activity of constitutively dimerized RET fusion proteins and activated point mutants, thereby blocking downstream signals for proliferation and survival. It is the first selective RET inhibitor to be FDA approved for tumor agnostic targeting of oncogenic RET fusion proteins. To view this Bench to Bedside, open or download the PDF.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Inibidores de Proteínas Quinases
/
Proteínas Proto-Oncogênicas c-ret
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Cell
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Canadá